Therefore, we suggest the MUC4 rs1104760 A>G polymorphism as a novel biomarker for CRC treatment because it is correlated with LDL-C levels and may affect inflammation in the intestine, thus inducing CRC development. Here, MUC4 is linked to colorectal carcinoma.